Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225099 | 0.84 | HPGD (0.47) | HPGDF10TSHR | |
| SCHEMBL8232859 | 0.83 | HPGD (0.47) | HPGDF10TSHR | |
| SCHEMBL8230688 | 0.83 | HPGD (0.47) | HPGDF10TSHR | |
| SCHEMBL8230480 | 0.81 | HPGD (0.45) | HPGDF10TSHR | |
| SCHEMBL3087908 | 0.81 | HPGD (0.53) | HPGDF10TSHR | |
| SCHEMBL1708736 | 0.80 | HPGD (0.52) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL3089664 | 0.80 | HPGD (0.52) | HPGDF10TSHR | |
| SCHEMBL8277767 | 0.77 | HPGD (0.49) | HPGDF10TSHR | |
| SCHEMBL1106605 | 0.77 | HPGD (0.49) | HPGDF10TSHRMEN1KMT2A | |
| SCHEMBL4908803 | 0.77 | HPGD (0.48) | HPGDF10TSHRPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | HPGD 4194/4885F10 2414/4885TSHR 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.